| Date |
Company |
Amount |
Funding type |
Investors |
Therapeutic area |
Type of Information |
| 2013-07-19 |
BioAlliance Pharma (France) |
€ 8.74 million |
issue of new shares |
Financière de la Montagne (France),IDInvest Partners (France) |
Cancer - Oncology - Rare diseases |
Capital increase |
| 2013-07-18 |
Tigenix (Belgium) |
€ 6.5 million |
private placement |
|
Bone diseases - Regenerative medicine - Rheumatic diseases |
Private placement |
| 2013-07-18 |
Summit (UK) |
AUD 1.25 million (€0.87 million) |
funding agreement |
Save Our Sons (Australia) |
Rare diseases - Neuromuscular diseases |
Fundraising |
| 2013-07-18 |
Absynth Biologics (UK) |
$1.2 million (€0.91 million) |
financing round |
The North West Fund for Biomedical (EU) Fusion IP (UK) |
Infectious diseases |
Financing round |
| 2013-07-18 |
Audentes Therapeutics (USA - CA) |
$30 million |
series A financing round |
|
Rare diseases - Genetic diseases |
Series A financing round |
| 2013-07-15 |
Cardio3 Biosciences (Belgium) |
€26.5 million |
IPO |
SRIW group, PMV , Kempen & Co |
Cardiovascular diseases |
IPO |
| 2013-07-15 |
Oss-Q AB, now OssDsign (Sweden) |
SEK 13.7million (€ 1.5 million) |
rights issue |
Karolinska Development (Sweden) |
Bone diseases - Regenerative medicine |
Private placement |
| 2013-07-11 |
Pathoquest (France) |
€ 3,8 million |
series B financing round |
Idinvest Partners (France) Aurinvest Capital (France) Kurma Biofund (France) |
Diagnostic |
Series B financing round |
| 2013-07-08 |
Prosensa (The Netherlands) |
$78 million (€60 million) |
IPO |
|
Rare diseases - Neuromuscular diseases |
IPO |
| 2013-07-08 |
Galapagos (Belgium) |
€2.4 million |
grant |
Flemish agency for Innovation by Science and Technology (IWT) (Belgium) |
Autoimmune diseases - Dermatological diseases |
Grant |
| 2013-07-08 |
OncoEthix (Switzerland) |
18 Million CHF (€ 14.5 million) |
series B financing round |
SV Life Sciences (SVLS) (UK-USA) Edmond de Rothschild Investment Partners (France) Index Ventures (Switzerland) Endeavour Vision (Switzerland) |
Cancer - Oncology |
Series B financing round |
| 2013-07-08 |
Sensorion (France) Griffin Discoveries (the Netherlands) |
€ 1.1 million |
grant |
|
Otorhinolaryngology |
Grant |
| 2013-07-04 |
Valneva |
€40.2 million |
capital increase |
FSI (France) Groupe Grimaud (France) Unigrains (France) |
Infectious diseases |
Capital increase |
| 2013-07-04 |
The GAPVAC consortium consists of 14 organizations from the biotech industry and academia with cutting-edge expertise in cancer vaccine development. The consortium is led by immatics biotechnologies GmbH (Coordinator) and BioNTech AG (Vice Coordinator). |
€6 million |
grant |
European Commission’s Seventh Framework Program (FP7) |
Cancer - Oncology |
Grant |
| 2013-07-03 |
Summit (UK) |
|
new share issue |
|
Rare diseases - Infectious diseases |
Private placement |
| 2013-07-03 |
BioAlliance Pharma (France) |
€4.3 million |
grant |
bpifrance (France) |
Cancer - Oncology |
Grant |
| 2013-07-03 |
Nanobiotix (France) |
€2.8 million |
grant
|
bpifrance (France) |
|
Grant |
| 2013-07-02 |
Moberg Pharma (Sweden) |
SEK 36 million |
new share issue |
Bure Equity (Sweden) |
Dermatological diseases |
Private placement |
| 2013-07-01 |
Autifony Therapeutics (UK) |
£1.9 million |
award |
Biomedical Catalyst Fund (UK) |
Otorhinolaryngology |
Grant |
| 2013-07-01 |
Galapagos (Belgium) |
€584,200.40 |
warrant exercises |
|
|
Private placement |
